The relative contributions of ecstasy and cannabis to cognitive impairment

Abstract. Rationale: (±)-3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'), a commonly used recreational drug, has typically been found to be related to poor cognitive function in humans. However, cannabis consumption may not have been adequately controlled for in these studies. Objective: The present study was designed to further elucidate the relation between MDMA and cannabis in cognitive impairment. Methods: Subjects who had used neither MDMA nor cannabis (controls; n=31), cannabis but not MDMA (cannabis users; n=18) and both MDMA and cannabis (MDMA/cannabis users; n=11) were compared on a battery of neuropsychological tests. Results: The cannabis and MDMA/cannabis groups did not differ on any of the tests, whereas the combined cannabis and MDMA/cannabis groups performed more poorly than controls on tests of memory, learning, word fluency, speed of processing and manual dexterity. Further, apart from speed of processing where higher MDMA consumption predicted slower processing, covariate analysis revealed that the deficits were more closely related to cannabis than MDMA usage. Conclusion: The results suggest that cannabis is an important confound in studies of MDMA-related cognitive impairment, and that previously reported cognitive impairment in MDMA users may have been caused by coincident cannabis use.

[1]  W. Slikker,et al.  Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. , 1989, Neurotoxicology.

[2]  G. Hanson,et al.  Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.

[3]  P. Gruenewald,et al.  Short-term memory impairment in cannabis-dependent adolescents. , 1989, American journal of diseases of children.

[4]  G. Ricaurte,et al.  Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.

[5]  U. McCann,et al.  Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.

[6]  G. Di Chiara,et al.  Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. , 1999, European Journal of Pharmacology.

[7]  A. Bloom.  Effect of delta9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. , 1982, The Journal of pharmacology and experimental therapeutics.

[8]  M. Naus,et al.  Cognitive correlates of long-term cannabis use in Costa Rican men. , 1996, Archives of general psychiatry.

[9]  R Hen,et al.  5-HT1B Receptor Knock-Out Mice Exhibit Increased Exploratory Activity and Enhanced Spatial Memory Performance in the Morris Water Maze , 1999, The Journal of Neuroscience.

[10]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[11]  J. Ridley.  Studies of Interference in Serial Verbal Reactions , 2001 .

[12]  D. Olton,et al.  3,4-Methylenedioxymethamphetamine, serotonin and memory. , 1993, The Journal of pharmacology and experimental therapeutics.

[13]  M. Geyer,et al.  Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans , 1999, Psychopharmacology.

[14]  Daniel L. Alkon,et al.  Calexcitin transformation of GABAergic synapses: from excitation filter to amplifier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Wilson,et al.  (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.

[16]  J. del Río,et al.  The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[17]  T. Simmet,et al.  Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices , 1999, British journal of pharmacology.

[18]  T. Steele,et al.  Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. , 1987, Biochemical pharmacology.

[19]  P. McGuire,et al.  Toxic effect of MDMA on brain serotonin neurons , 1999, The Lancet.

[20]  M. Morgan.  Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.

[21]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[22]  K. Zakzanis,et al.  Memory impairment in abstinent MDMA (“Ecstasy”) users: A longitudinal investigation , 2001, Neurology.

[23]  L. Bérubé,et al.  [Clinical neuropsychology]. , 1982, Nursing Quebec.

[24]  U. McCann,et al.  Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.

[25]  M. Petrides.  Deficits on conditional associative-learning tasks after frontal- and temporal-lobe lesions in man , 1985, Neuropsychologia.

[26]  A. Lees,et al.  Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits , 1998, Journal of psychopharmacology.

[27]  Patrick J. O'Donnell,et al.  Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence , 1999, Psychopharmacology.

[28]  D. Taylor,et al.  Modulation by fluoxetine of striatal dopamine release following Δ9‐tetrahydrocannabinol: a microdialysis study in conscious rats , 1999, British journal of pharmacology.

[29]  G. Gessa,et al.  Permissive Role of Dopamine D2 Receptors in the Hypothermia Induced by Δ9-Tetrahydrocannabinol in Rats , 2000, Pharmacology Biochemistry and Behavior.

[30]  J. Sweeney,et al.  Drug abuse in schizophrenic patients: clinical correlates and reasons for use. , 1991, The American journal of psychiatry.

[31]  Y. Shaham,et al.  Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.

[32]  A. Scallet.  Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals , 1991, Pharmacology Biochemistry and Behavior.

[33]  Z. Szabo,et al.  In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.

[34]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[35]  S. Robinson,et al.  (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats. , 1987, European journal of pharmacology.

[36]  G. Chiara,et al.  Dependence of mesolimbic dopamine transmission on Δ9-tetrahydrocannabinol , 1999 .

[37]  M. Morgan.  Recreational Use of “Ecstasy” (MDMA) Is Associated with Elevated Impulsivity , 1998, Neuropsychopharmacology.

[38]  M. Colado,et al.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.

[39]  R. Branconnier,et al.  Cannabis: effects on memory and the cholinergic limbic system. , 1983, Psychological bulletin.

[40]  D E Nichols,et al.  An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.

[41]  G. Gessa,et al.  Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats. , 2000, Pharmacology, biochemistry, and behavior.

[42]  K. L. Jansen,et al.  Ecstasy (MDMA) dependence. , 1999, Drug and alcohol dependence.

[43]  J. Fisk,et al.  Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.